Shattuck Labs Inc (STTK)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$6.79-2.44%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · STTK
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Initiate and progress the Phase 2b clinical trial of SL-325, a DR3 blocking antibody, to establish efficacy and safety in Crohn's disease patients.
Stated as a priority in 3 of last 3 quarters. Management consistently communicated the initiation of the Phase 2b clinical trial of SL-325 in Crohn's disease patients expected in Q3 2026, with primary endpoint data anticipated in the first half of 2028. The trajectory is delivering as the trial initiation remains on track.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 0 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated weak grew net income 28% of the time over the next year (vs 52% for the rest of the cohort, n=10029).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
“RECEPTIVE-CD1 Phase 2b clinical trial of SL-325 in patients with Crohn's disease expected to initiate in the third quarter of 2026.”
“Shattuck expects to initiate a Phase 2 clinical trial of SL-325 in patients with Crohn's disease in the third quarter of 2026.”
“RECEPTIVE-CD1 Phase 2b clinical trial in patients with Crohn's disease expected to initiate in the third quarter of 2026.”
Advance the lead bispecific DR3 x IL-23 receptor blocking antibody SL-846 through IND-enabling studies and initiate Phase 1 clinical trial in 2027.
Stated as a priority in 3 of last 3 quarters. Management has consistently reported SL-846 is undergoing IND-enabling toxicology studies with a Phase 1 clinical trial planned for the first half of 2027. The development timeline is on track with no reported delays.
“Announced lead bispecific antibody candidate SL-846 with initial Phase 1 clinical data expected in 2027.”
“Lead bispecific antibody has entered IND-enabling activities; expected development timelines disclosed in Q2 2026.”
“SL-846 currently being evaluated in IND-enabling GLP toxicology study; Phase 1 initiation expected in first half of 2027.”
Ensure sufficient cash and cash equivalents, including proceeds from stock offerings, to fund operations through 2029.
Stated as a priority in 4 of last 4 quarters. Cash and cash equivalents plus short-term investments increased from approximately $82.5 million at 2025-Q4 to $213.3 million at 2026-Q2, supported by equity offerings and warrant exercises. Management's guidance consistently projects funding operations into 2029, indicating delivery on this priority.
“Cash and cash equivalents and short-term investments of $208.3 million expected to fund operations into 2029.”
“Cash and cash equivalents of $90.4 million expected to fund operations into 2029 assuming full exercise of warrants.”
“Cash and cash equivalents and short-term investments including $21.4 million ATM proceeds expected to fund operations into 2029.”
“Cash and cash equivalents and short-term investments expected to fund operations into 2029 assuming full exercise of warrants.”
Shattuck aims to fund its operations into 2029 through current cash, cash equivalents, and stock warrants.
Shattuck is utilizing stock offerings to maintain cash flow and fund operations.
Over the trailing year it converted 0.94x of net income into operating cash flow.
Not enough signal yet.
Not enough signal to read sensitivity to the broad stock market, Fed net liquidity, real (inflation-adjusted) rates, long-term interest rates, the US dollar (low R² over the window).
9 material management or governance events in the past 24 months, led by capital-allocation actions. Historically, Health Care names rated stable grew net income 46% of the time over the next year (vs 53% for the rest of the cohort, n=3872).
Not investment advice. As of 2026-09-04.